Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dog dander allergen extract
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
ALK Alutard SQ Dog is a subcutaneous allergen immunotherapy (SCIT) product containing standardized allergen extracts from dog dander (*Canis familiaris*). Developed by ALK-Abelló, it is indicated for the treatment of moderate-to-severe dog-induced allergic rhinitis and allergic asthma. The extract is adsorbed onto aluminum hydroxide, which acts as an adjuvant and provides a slow-release depot effect at the injection site. The therapy works by modifying the underlying allergic disease through the induction of immune tolerance, characterized by a shift from a Th2-mediated allergic response to a Th1/Treg-mediated response, increased production of IL-10 and TGF-beta, and the generation of allergen-specific IgG4 blocking antibodies that prevent IgE-mediated mast cell degranulation.
- Brand names
- Alutard SQ DogAlutard SQ
- Other names
- Dog allergen extractCanis familiaris allergen extract
02
Targets
Dog allergen-derived peptide-MHC class II complexB-cell receptor specific for dog allergensIgE (Immunoglobulin E)Major histocompatibility complex class II–dog allergen peptide–T-cell receptor complex
Beyond the preview
Go deeper on dog dander allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dog dander allergen extract.